

August 21, 2026

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd.,

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Completion of Unannounced US FDA Inspection at the facility of Caplin Steriles Limited (Company's Subsidiary)

This is to inform you that the United States Food and Drug Administration (US FDA) conducted an unannounced inspection of Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi. The inspection was conducted between August 13, 2026, and August 21, 2026. At the end of the inspection, the Company received Form 483 with 10 (ten) observations. The observations are procedural in nature and does not pertain to data integrity and none of them were repeat observations.

The Company is addressing the observations comprehensively and will respond to the US FDA within the stipulated timeframe.

Kindly take the same on your records.

Sincerely Yours

For Caplin Point Laboratories Limited

Venkatram G
General Counsel & Company Secretary
Membership No A23989